|
Restructuring Activities
|
6 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2011
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring Activities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RESTRUCTURING ACTIVITIES |
6. RESTRUCTURING ACTIVITIES
On August 21, 2008, Sonus Pharmaceuticals, Inc., or Sonus, completed a transaction, or “the
Arrangement”, with OncoGenex Technologies whereby Sonus acquired all of the outstanding preferred
shares, common shares and convertible debentures of OncoGenex Technologies. Sonus then changed its
name to OncoGenex Pharmaceuticals, Inc. Prior to the Arrangement, Sonus entered into a
non-cancellable lease arrangement for office space located in Bothell, Washington, which is
considered to be in excess of the Company’s current requirements. The Company is currently in the
process of evaluating opportunities to exit or sublet portions of the leased space and recorded an
initial restructuring charge of $2,084,000 on August 21, 2008 as part of the purchase price
allocation. The liability is computed as the present value of the difference between the remaining
lease payments due less the estimate of net sublease income and expenses and has been accounted for
in accordance with the then effective EITF No. 95-3, “Recognition of Liabilities in Connection with
a Purchase Business Combination”. This represents the Company’s best estimate of the liability.
Subsequent changes in the liability due to changes in estimates of sublease assumptions are
recognized as adjustments to restructuring charges.
In June 2009, the Company revised its sublease income assumptions used to estimate the excess lease
facility liability. These assumptions were subsequently revised again in December 2009 and
September
2010. These changes in estimate resulted in increases in the value of the excess lease liability of
$494,000, $3,457,000, and $4,038,000 and a corresponding expense recorded in June 2009, December
2009, and September 2010, respectively, to reflect these changes in estimate. The estimated value
of the liability remaining with respect to excess facilities was $7,467,000 as of December 31,
2010. In the six months ended June 30, 2011, with respect to excess facilities, $140,000 was
amortized into income resulting in a remaining liability of $7,327,000 at June 30, 2011.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||